Get to know BIOMIMETICS SYMPATHIES
in three minutes
Let us briefly introduce the features of BIOMIMETICS SYMPATHIES’
business divided into three main points.
A company tackling
BIOMIMETICS SYMPATHIES pioneered work on regenerative medicine in Japan. We promptly started research development and clinical development with a focus on “mesenchymal stem cells (MSC)” as a hope of treatment for refractory diseases. We will contribute to the future of patients and healthcare by conducting research and development on products, including media and new technologies, and providing technical support to various companies and research institutions involved in healthcare.
Provider of “safe” and
“effective” cell culture media
Our company has developed Animal Origin Free (AOF) medium that does not contain any animal-derived components, including those from humans, associated with high safety, growth, and cell modification quality. Above all, we strive to ensure the safety of patients to whom cells are administered and corresponding therapeutic effects by providing culture media/cell culture technologies and know-how appropriate for each disease.
Our company has experience in providing AOF media and MSC culture technologies to large pharmaceutical companies and medical institutions within Japan and overseas. We have also conducted multiple joint research and development projects with Japan’s leading universities and research institutions. We own proprietary culture technologies and have the corresponding know-how, as well as multiple patents, and execute licensing agreements with companies within Japan and overseas.